Ribo Secures Series E Funding to Accelerate Global siRNA Therapeutics Strategy
Suzhou Ribo Life Science Co., Ltd. ("Ribo"), a global leader in siRNA therapeutics, today announced the successful completion of its Series E financing round, raising over RMB 200 million (approximately $28 million). The round was led by Mingxin Capital, with participation from prominent investors including Kunshan High-Tech VC, Kunshan Guokai VC, Chouqin VC, Panlin Capital, Everest VC, and Shenzhen Xinchuang Yihe.
The proceeds will accelerate clinical development across cardiovascular, metabolic, renal, and hepatic disease pipelines while advancing the Company's proprietary extrahepatic delivery technology platform. The capital injection will further strengthen Ribo’s global R&D capabilities and industrial infrastructure. Since inception, Ribo has raised over RMB 1.8 billion (∼$250 million) from top-tier investors, evolving from a pioneer in China's oligonucleotide space to a global siRNA frontrunner. With strategic R&D centers in Suzhou, Beijing (China) and Gothenburg (Europe), the Company has established an integrated development system covering the entire siRNA drug lifecycle – from discovery to commercialization.
Dr. Zicai Liang, Chairman and CEO, emphasized: "With our investors' steadfast support, Ribo has achieved transformative breakthroughs in both platform technologies and clinical pipelines. We remain committed to global leadership through our dual-engine strategy combining international product development and proprietary innovation."
Dr. Lixing Xu, Founding Partner of Mingxin Capital, noted: "siRNA represents the most disruptive modality in biopharma today, offering superior dosing frequency, patient compliance, and development efficiency compared to traditional therapies. As the category leader with multiple clinical-stage assets, Ribo's world-class team exemplifies global excellence. We're proud to lead this round through Jinan Mingxin Industrial Investment Fund and will actively support their international expansion."
About Mingxin Capital
Founded in 2006, Mingxin Capital is an international private investment fund focused on high-tech enterprises in the growing period. By gathering its global resources, Mingxin Capital is committed to help Chinese biotech’s expansion in international market and to grow into the world-leading enterprises.
About Kunshan High-tech VC
Established in 2012, Kunshan High-Tech Venture Capital Co., Ltd. (Kunshan High-Tech VC) is a state-owned venture capital platform wholly owned by Kunshan High-Tech Group Co., Ltd. With a registered capital of RMB300 million, it operates through a dual-driven model combining direct investments and fund investments. Specializing in equity investments and industrial incubation, Kunshan High-Tech VC mainly focus on and continuously invest in various new modalities in key sectors including information technology, intelligent manufacturing, biopharmaceutical, new energy, and advanced materials. Kunshan High-Tech VC is one of existing shareholders of Ribo.
About Kunshan Guoke VC
Established in 2001 and with a registered capital of RMB725 million, Kunshan Guoke Venture Capital Co., Ltd. (Kunshan Guoke VC) is a venture capital investor controlled by Kunshan Venture Capital Holding Co., Ltd, engaging in venture investment in high-tech enterprises and technological innovation enterprises and venture capital funds management. Kunshan Guoke VC mainly focuses on investment in electronics, metal materials, biopharmaceutical, chip design, sophisticated equipment, rapid prototyping manufacturing, optoelectronic industry etc., laying a solid foundation for the development of related industries in Kunshan. Kunshan Guoke VC is one of the existing shareholders of Ribo.
About Chouqin VC
Chouqin Venture Capital was established in 2015, with investment areas specialized in healthcare, information technology, sophisticated manufacturing etc. Its investment portfolio includes Unocal Bioengineering, SuZhou Agilebio, Xipu Sunshine, Enginetech etc. Chouqin VC participated in Ribo’s previous round of financing.
About Panlin Capital
Panlin Capital is a Venture Capital highly renowned for its expertise and influence in both healthcare and technology sectors. Founded in 2010, Panlin adheres to the investment philosophy of "Technology Creates the Future, Innovation Leads the Upgrade.", targets the start-ups with the aim to "identify the entrepreneurs among scientists and enable the innovators among entrepreneurs".
In healthcare field, Panlin invests in innovative drug developers targeting unmet clinical needs for major diseases, as well as medical device innovators, while exploring derivative investment opportunities in life sciences and biotechnology. For technology investments, Panlin targets the To B enterprises (enterprise services and data intelligence solutions) addressing the B2B demand for cost reduction, efficiency enhancement, and quality improvement, and Hard & Core technical enterprises (equipment and key components) meeting the requirement for technological self-sufficiency in critical technologies.
Prior to this round, Panlin had led or participated in five consecutive rounds and is the most supportive investor of Ribo.
About Zhuhai RuanYin XinChuang
Zhuhai RuanYin XinChuang, the fund manager of Shenzhen XinChuang Yihe, is a RMB venture capital and private equity fund management company dedicated to investing in high-growth, high-tech enterprises across Greater China. Its founders were from SoftBank China Capital (SBCVC)'s healthcare sector, having successfully invested in outstanding companies such as DA Diagnostics, BGI Genomics, Lifotronic, and Edan Instruments. Its investment portfolio primarily covers healthcare sectors including cell and gene therapy, AI and digital medicine, synthetic biology, and neuroscience.
About Everest VC
Founded in September 2007, Everest VC operates offices in Beijing, Shenzhen and Shanghai, with worldwide investment coverage high-tech sectors including healthcare, semiconductors, AI, advanced manufacturing, automotive transportation, and new energy. To date, Everest has invested in 128 companies, including 38 listed enterprises, and over10 are in IPO approval or listing process. Over its 18-year journey, Everest has been consistently empowering innovative startups with rapid growth. Through strategic investment insights and professional strategies, Everest provides capital and resources to help these enterprises distinguish themselves in the market and achieve rapid expansion. Additionally, by launching venture capital funds, Everest enables investors to share the growth dividends of high-tech companies, gaining widespread trust and recognition within the investment industry.